Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 5/2023

27-05-2023 | Dabigatran | IM - COMMENTARY

Direct oral anticoagulants in patients with bioprosthetic heart valves

Author: Giulia Renda

Published in: Internal and Emergency Medicine | Issue 5/2023

Login to get access

Excerpt

Non-vitamin K oral anticoagulants, also known as direct oral anticoagulants (DOACs), due to their direct inhibition of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, and edoxaban) are safe and efficacious alternatives to vitamin K antagonists (VKAs) for the prevention of thromboembolism in atrial fibrillation (AF) and they are recommended in preference to VKAs in AF patients eligible to oral anticoagulants (excluding those with moderate-to-severe mitral stenosis or mechanical heart valves) [1]. …
Literature
1.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373–498CrossRefPubMed
2.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed
3.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104CrossRefPubMed
4.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMed
5.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMed
6.
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369(13):1206–1214CrossRefPubMed
7.
Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A et al (2022) Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 387(11):978–988CrossRefPubMed
8.
Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M et al (2015) Apixaban in comparison with warfarin in patients with atrial fibrillation and Valvular heart disease: findings from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) Trial. Circulation 132(8):624–632CrossRefPubMed
9.
Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR et al (2014) Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 35(47):3377–3385CrossRefPubMedPubMedCentral
10.
De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF et al (2017) Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 69(11):1372–1382CrossRefPubMed
11.
Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M et al (2016) Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation 134(8):589–598CrossRefPubMed
12.
Renda G, Ricci F, Giugliano RP, De Caterina R (2017) Non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol 69(11):1363–1371CrossRefPubMed
13.
14.
Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M et al (2017) Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 135(13):1273–1275CrossRefPubMed
15.
Guimaraes HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F et al (2020) Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 383(22):2117–2126CrossRefPubMed
16.
Duan L, Doctor JN, Adams JL, Romley JA, Nguyen LA, An J et al (2021) Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol 146:22–28CrossRefPubMed
17.
Duraes AR, de Souza RP, de Almeida NB, Albuquerque FP, de Bulhoes FV, de Souza Fernandes AM et al (2016) Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D 16(2):149–154CrossRefPubMedPubMedCentral
18.
Piepiorka-Broniecka M, Michalski TA, Figatowski T, Wojtowicz A, Jurowiecki J, Stanska A et al (2022) NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement. Cardiol J 29(2):355–357CrossRefPubMedPubMedCentral
19.
Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S et al (2023) Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg 165(1):58-67.e4CrossRefPubMed
20.
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2022) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43(7):561–632CrossRefPubMed
21.
Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR et al (1995) High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25(5):1111–1119CrossRefPubMed
22.
Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS et al (2012) Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol 60(11):971–977CrossRefPubMed
23.
Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J et al (2012) Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308(20):2118–2125CrossRefPubMed
24.
Rafiq S, Steinbruchel DA, Lilleor NB, Moller CH, Lund JT, Thiis JJ et al (2017) Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial. Thromb Res 150:104–110CrossRefPubMed
25.
Calabro P, Gragnano F, Niccoli G, Marcucci R, Zimarino M, Spaccarotella C et al (2021) Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease. Circulation 144(16):1323–1343CrossRefPubMed
26.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, Lopez-Otero D et al (2021) Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 385(23):2150–2160CrossRefPubMed
27.
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F et al (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 143(5):e72–e227PubMed
Metadata
Title
Direct oral anticoagulants in patients with bioprosthetic heart valves
Author
Giulia Renda
Publication date
27-05-2023

Other articles of this Issue 5/2023

Internal and Emergency Medicine 5/2023 Go to the issue

Correction

Correction to: Antibiotic prescriptions in the context of suspected bacterial respiratory tract superinfections in the COVID-19 era: a retrospective quantitative analysis of antibiotic consumption and identification of antibiotic prescription drivers

REVIEW

Crohn’s disease and breast cancer: a literature review of the mechanisms and treatment

CE - MEDICAL ILLUSTRATION

IgG4-related disease presenting with recurrent abdominal pain: a long way until the diagnosis

IM - ORIGINAL

Biomarkers of exposure and potential harm in exclusive users of electronic cigarettes and current, former, and never smokers

IM-Point of view

Hemophilia patients: are they naturally anticoagulated?

IM - ORIGINAL

Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy, Italy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits